Compare Nano Dimension Ltd - ADR (NNDM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs GeneDx Holdings Corp — how do they compare? Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 6.1× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and GeneDx Holdings Corp for 19 Days on average.
| NNDM | WGS | |
|---|---|---|
Market Cap | $328.52M | $2.02B |
Volume | 1,160,945 | 734,640 |
Sector | Technology | Health |
52-Week High | $2.14 | $167.51 |
52-Week Low | $1.21 | $34.51 |
Typical Hold Time | 43 Days | 19 Days |
Enterprise Value | -$76.33M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.555, showing modest daily gains of 0.32%. The technical picture remains bearish with negative moving average signals, while fundamentals reveal significant challenges including a -135.18% net income margin and persistent cash burn. Recent developments include leadership changes and strategic divestitures aimed at reducing annual cash burn by $25 million, with the MarkForged sale expected to close in late 2026.
Despite trading below book value (P/B 0.68), NNDM faces substantial execution risks amid ongoing losses and negative cash flow. The company's restructuring efforts and asset sales provide potential catalysts, but investors should weigh the high-risk profile against the discounted valuation. Near-term performance hinges on successful cost reduction and revenue stabilization.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
